Posted by Michael Wonder on 24 May 2018
Teva confirms September PDUFA date for fremanezumab
23 May 2018 - May 23, 2018-- Teva Pharmaceutical Industries today confirmed that the U.S. FDA has extended the goal date of the biologics license application for fremanezumab, an investigational therapy for the preventive treatment of migraine.
The Prescription Drug User Fee Act action date for fremanezumab is set for 16 September 2018. There are no additional data requests from the FDA.
